Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mixed news on supplements

This article was originally published in The Tan Sheet

Executive Summary

NPR's "Talk of the Nation" plans to air an upcoming series on supplement use called "Do No Harm," which will likely examine supplement-drug interactions, and the network's "All Things Considered" will run a feature on alternative medicine in the near future. The radio broadcasts will be the latest installments in a flurry of recent media coverage on supplements. A June 20 New York Times article highlighted the work of, while the Washington Post ran a piece June 18 about supplement products for children and recently carried a story on a Virginia woman who suffered seizures after taking ephedrine. CBS News' "48 Hours" featured a story entitled "Living Better Longer" June 15, with a segment on actor Nick Nolte's supplement use, a piece on nationally syndicated radio host Dr. Dean Edell, who was highly critical of supplements, and the story of a woman hospitalized due to herbal-drug interactions

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts